Enterprise Therapeutics Ltd, a Brighton, England, UK-based drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, raised funding from the Cystic Fibrosis Trust.
The funding – of undisclosed amount – will be used to identify new drug mechanisms for the treatment of cystic fibrosis (CF).
Led by Dr John Ford, CEO, Enterprise Therapeutics has developed a technology platform which leverages bronchosphere, a miniaturized model of the human airway that can be used to support high-throughput drug and target discovery and to facilitate the development of new classes of therapeutics for the treatment of cystic fibrosis.
FinSMEs
05/04/2017